Frontiers in tuberculosis · 2026
Implementation of sequencing-based surveillance for drug-resistant tuberculosis in Nigeria.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McLaughlin Heather P, Audu Israel, Tola Monday, Onwuamah Chika Kingsley, Ogwu Julius, Atoe Kenneth, Kunle-Ope Chioma Nneka, Ahmadu Isiyaku, Gowon Joshua, Meshak David B, Iwakun Mosunmola, Ude Chinedu Ejianya, Abiona Modupe, Momoh Abidemi Esther, Ore Temiloluwa, Ogbu Chinenye Angela, Abiodun Temitope Abigail, Dawson Jamie, Hall-Eidson Patricia, Iriemenam Nnaemeka C, Okoye McPaul, Adesigbin Clement, Chijioke-Akaniro Obioma, Emeka Elom, Chukwuma Anyaike
Аннотация
Sequencing for drug-resistant tuberculosis (DR-TB) surveillance was established in Nigeria for the first time, demonstrating a nationally coordinated referral network for multi-disease sequencing services. Mycobacterium tuberculosis isolates previously identified as resistant to rifampicin and/or isoniazid by genotypic or phenotypic drug susceptibility testing were selected proportionately across all six geopolitical zones in Nigeria. Programmatic use of sequence data for DR-TB surveillance was prioritized, demonstrating additional resistance detection and enhanced monitoring as new TB treatment regimens are scaled up. Sanger sequencing identified resistance to rifampicin and isoniazid missed by drug susceptibility tests routinely used in country, for 11% (5/47) and 2% (1/47) of isolates, respectively. This pilot study demonstrates feasibility and provides an example for programmatic implementation of integrated sequencing, supporting country efforts to strengthen genomic surveillance for DR-TB and improve prevention and control globally.